Eight-Year Experience with a Continuous-Flow Total Artificial Heart in Calves

Cohn, William E.; Handy, Kelly M.; Parnis, Steven M.; Conger, Jeffrey L.; Winkler, Jo Anna; Frazier, O. H.

ASAIO Journal:
doi: 10.1097/MAT.0000000000000027
Adult Circulatory Support

Over the last 8 years, we have developed and evaluated a continuous-flow total artificial heart (CFTAH) comprising two rotary blood pumps. To understand the physiologic effects of nonpulsatile circulation, we evaluated the CFTAH in 65 calves for 90 days or less. We describe our experience with 29 calves that survived for 7 days or more. The calves received dual axial-flow (n = 24) or centrifugal-flow (n = 5) pumps. Several iterations of customized atrial cuffs were developed to facilitate an adequate anatomical fit. Pressures (arterial pressure [AoP], pulmonary artery pressure [PAP], left atrial pressure [LAP], and right atrial pressure [RAP]) and pump parameters were continuously monitored. Hematologic and biochemistry values were analyzed. After each case, a necropsy was performed. The calves survived for 7–92 days (mean, 24 days). Pressures were 94 ± 14 (AoP), 25 ± 8 (PAP), 14 ± 6 (RAP), and 16 ± 6 (LAP) mm Hg. Pump flow was maintained at 9.1 ± 1.7 L/minute (right) and 9.4 ± 1.9 L/minute (left). Hematologic and biochemistry values remained acceptable. Eight animals underwent treadmill evaluations, in which oxygen consumption (VO2) was comparable with physiologic total-body VO2. In the two animals that survived to 90 days, the end-organs appeared unremarkable at autopsy, and the CFTAH circuits were free of thrombus. Our results show that a CFTAH can maintain a large animal physiologically and hemodynamically for up to 90 days with continuous flow.

Author Information

From the Cardiovascular Research Laboratories, Texas Heart Institute at St. Luke’s Hospital, Houston, Texas.

Submitted for consideration April 2013; accepted for publication in revised form October 2013.

The project described was supported by Grant Numbers R01HL085054 and R01HL090521 awarded to the Texas Heart Institute (THI) by the National Heart, Lung, and Blood Institute (NHLBI). The content is solely the responsibility of the authors and does not necessarily represent the official views of NHLBI or the National Institutes of Health.

Disclosure: The authors have no conflicts of interest to report.

Reprint Requests: O. H. Frazier, Cardiovascular Research Laboratories, Texas Heart Institute at St. Luke’s Hospital, PO Box 20345, MC 2-114A, Houston, TX 77225-0345. Email: lschwenke@heart.thi.tmc.edu.

Copyright © 2014 by the American Society for Artificial Internal Organs